logo

AMRX

Amneal·NASDAQ
--
--(--)
--
--(--)
2.13 / 10
Underperform

AMRX's fundamental health is rated weak (2.1/10). Key concerns include stagnant year-over-year revenue growth (0% YoY) and modest net profit margin (93.3%), offset by a positive interest-coverage ratio (1.45). The composite fundamental score of 2.13 underscores the need for improvement in top-line expansion and overall profitability to attract deeper value investors.

Fundamental(2.13)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value0.74
Score2/3
Weight25.52%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value6.83
Score1/3
Weight-1.08%
1M Return-0.60%
Inventory turnover ratio
Value2.26
Score3/3
Weight-2.01%
1M Return-1.05%
Profit-MV
Value0.18
Score2/3
Weight20.62%
1M Return8.99%
PB-ROE
Value-0.19
Score1/3
Weight20.85%
1M Return8.79%
Interest coverage ratio (EBIT / Interest expense) (%)
Value1.45
Score2/3
Weight-2.22%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value6.83
Score1/3
Weight-0.94%
1M Return-0.52%
Asset-MV
Value-0.51
Score1/3
Weight21.23%
1M Return8.68%
Net profit / Total profit (%)
Value93.31
Score2/3
Weight-1.76%
1M Return-0.98%
Cash-MV
Value0.33
Score2/3
Weight19.79%
1M Return8.80%
Is AMRX undervalued or overvalued?
  • AMRX scores 2.13/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, 1.96% net margin, 1352.46 P/E ratio, -108.23 P/B ratio, and 102.33% earnings growth, these metrics solidify its Underperform investment rating.